Kyverna Therapeutics Inc KYTX
News
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
